Can Amazon become OpenAI’s next cloud partner? $10bn deal could reshape AI race
OpenAI is in talks with Amazon for a $10B investment and chip deal. Find out how it could reshape cloud AI infrastructure and challenge Microsoft’s lead.
Pennsylvania American Water expands wastewater footprint with $28m Elizabeth Borough acquisition
Find out how Pennsylvania American Water’s $28M acquisition of Elizabeth Borough’s sewer system could reshape utility ownership in Pennsylvania.
Ariston Group strikes €289m deal to acquire Riello from Carrier Global
Ariston acquires Riello from Carrier for €289M, expanding clean combustion reach and boosting presence in Italy and North America. Read the full analysis.
Can OrsoBio’s TLC-6740 combination data reopen the race for post-GLP obesity differentiation?
OrsoBio’s TLC-6740 combo data hints at a new way to extend GLP-1 weight loss without higher doses. Read what this means for obesity drug development.
How Cosette Pharmaceuticals used CGT exclusivity to unlock a long-ignored ear infection drug market
Cosette Pharmaceuticals secures FDA approval with CGT exclusivity for a long-protected otic drug. Read what this signals for specialty generics.
BlueWind Medical secures FDA clearance for enhanced Revi wearable as neuromodulation adoption shifts
BlueWind Medical secures FDA clearance for an enhanced Revi wearable. Find out why adherence, not efficacy, is shaping neuromodulation strategy.
NETSOL Technologies extends long-term auto finance partnership with $50m four-year deal
Discover why NETSOL Technologies’ $50 million contract extension signals deeper institutional trust and long-term strength in global auto finance software.
What Flux Power’s latest $3.6m airline eGSE orders reveal about aviation electrification adoption
Flux Power secures over $3.6 million in repeat airline eGSE orders. Discover what this means for aviation electrification, investors, and clean energy markets.
I-SPY 2 data puts Natera’s Signatera at the center of early breast cancer risk debates
Natera’s I-SPY 2 data suggests ctDNA may finally align early breast cancer risk with treatment intensity. Read why this matters for payers and markets.
Why AlphaTON Capital’s $30m Anduril Industries investment could change how Wall Street taps private defense tech
AlphaTON Capital’s $30 million investment in Anduril Industries signals a new model for public access to private defense technology. Find out why it matters now.